SAMPLE_NAME	COSMIC_SAMPLE_ID	GENE_SYMBOL	COSMIC_GENE_ID	TRANSCRIPT_ACCESSION	CENSUS_GENE	DRUG_NAME	DRUG_RESPONSE	GENOMIC_MUTATION_ID	LEGACY_MUTATION_ID	MUTATION_ID	MUTATION_AA	MUTATION_CDS	GENOMIC_WT_ALLELE	GENOMIC_MUT_ALLELE	COSMIC_PHENOTYPE_ID	PUBMED_PMID	COSMIC_STUDY_ID	MUTATION_ZYGOSITY	CHROMOSOME	GENOME_START	GENOME_STOP	STRAND	HGVSP	HGVSC	HGVSG	MUTATION_SOMATIC_STATUS
1000815	COSS1000815	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	22472073	p.T790M	c.2369C>T	C	T	COSO29974826	16983123			7	55249071	55249071	+	ENSP00000275493.2:p.Thr790Met	ENST00000275493.2:c.2369C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1000815	COSS1000815	EGFR	COSG35617	ENST00000442591.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	58365907	p.?	c.*28+8450C>T	C	T	COSO29974826	16983123			7	55249071	55249071	+		ENST00000442591.1:c.*28+8450C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1000815	COSS1000815	EGFR	COSG35617	ENST00000454757.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	61857897	p.T737M	c.2210C>T	C	T	COSO29974826	16983123			7	55249071	55249071	+	ENSP00000395243.2:p.Thr737Met	ENST00000454757.2:c.2210C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1000815	COSS1000815	EGFR	COSG35617	ENST00000455089.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	62640703	p.T745M	c.2234C>T	C	T	COSO29974826	16983123			7	55249071	55249071	+	ENSP00000415559.1:p.Thr745Met	ENST00000455089.1:c.2234C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1000816	COSS1000816	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	22472073	p.T790M	c.2369C>T	C	T	COSO29974826	16983123			7	55249071	55249071	+	ENSP00000275493.2:p.Thr790Met	ENST00000275493.2:c.2369C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1000816	COSS1000816	EGFR	COSG35617	ENST00000442591.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	58365907	p.?	c.*28+8450C>T	C	T	COSO29974826	16983123			7	55249071	55249071	+		ENST00000442591.1:c.*28+8450C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1000816	COSS1000816	EGFR	COSG35617	ENST00000454757.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	61857897	p.T737M	c.2210C>T	C	T	COSO29974826	16983123			7	55249071	55249071	+	ENSP00000395243.2:p.Thr737Met	ENST00000454757.2:c.2210C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1000816	COSS1000816	EGFR	COSG35617	ENST00000455089.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	62640703	p.T745M	c.2234C>T	C	T	COSO29974826	16983123			7	55249071	55249071	+	ENSP00000415559.1:p.Thr745Met	ENST00000455089.1:c.2234C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1000817	COSS1000817	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	22472073	p.T790M	c.2369C>T	C	T	COSO29974826	16983123			7	55249071	55249071	+	ENSP00000275493.2:p.Thr790Met	ENST00000275493.2:c.2369C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1000817	COSS1000817	EGFR	COSG35617	ENST00000442591.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	58365907	p.?	c.*28+8450C>T	C	T	COSO29974826	16983123			7	55249071	55249071	+		ENST00000442591.1:c.*28+8450C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1000817	COSS1000817	EGFR	COSG35617	ENST00000454757.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	61857897	p.T737M	c.2210C>T	C	T	COSO29974826	16983123			7	55249071	55249071	+	ENSP00000395243.2:p.Thr737Met	ENST00000454757.2:c.2210C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1000817	COSS1000817	EGFR	COSG35617	ENST00000455089.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	62640703	p.T745M	c.2234C>T	C	T	COSO29974826	16983123			7	55249071	55249071	+	ENSP00000415559.1:p.Thr745Met	ENST00000455089.1:c.2234C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024758	COSS1024758	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	22472073	p.T790M	c.2369C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+	ENSP00000275493.2:p.Thr790Met	ENST00000275493.2:c.2369C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024758	COSS1024758	EGFR	COSG35617	ENST00000442591.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	58365907	p.?	c.*28+8450C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+		ENST00000442591.1:c.*28+8450C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024758	COSS1024758	EGFR	COSG35617	ENST00000454757.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	61857897	p.T737M	c.2210C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+	ENSP00000395243.2:p.Thr737Met	ENST00000454757.2:c.2210C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024758	COSS1024758	EGFR	COSG35617	ENST00000455089.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	62640703	p.T745M	c.2234C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+	ENSP00000415559.1:p.Thr745Met	ENST00000455089.1:c.2234C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024765	COSS1024765	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	22472073	p.T790M	c.2369C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+	ENSP00000275493.2:p.Thr790Met	ENST00000275493.2:c.2369C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024765	COSS1024765	EGFR	COSG35617	ENST00000442591.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	58365907	p.?	c.*28+8450C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+		ENST00000442591.1:c.*28+8450C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024765	COSS1024765	EGFR	COSG35617	ENST00000454757.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	61857897	p.T737M	c.2210C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+	ENSP00000395243.2:p.Thr737Met	ENST00000454757.2:c.2210C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024765	COSS1024765	EGFR	COSG35617	ENST00000455089.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	62640703	p.T745M	c.2234C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+	ENSP00000415559.1:p.Thr745Met	ENST00000455089.1:c.2234C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024766	COSS1024766	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	22472073	p.T790M	c.2369C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+	ENSP00000275493.2:p.Thr790Met	ENST00000275493.2:c.2369C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024766	COSS1024766	EGFR	COSG35617	ENST00000442591.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	58365907	p.?	c.*28+8450C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+		ENST00000442591.1:c.*28+8450C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024766	COSS1024766	EGFR	COSG35617	ENST00000454757.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	61857897	p.T737M	c.2210C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+	ENSP00000395243.2:p.Thr737Met	ENST00000454757.2:c.2210C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024766	COSS1024766	EGFR	COSG35617	ENST00000455089.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	62640703	p.T745M	c.2234C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+	ENSP00000415559.1:p.Thr745Met	ENST00000455089.1:c.2234C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024768	COSS1024768	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	22472073	p.T790M	c.2369C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+	ENSP00000275493.2:p.Thr790Met	ENST00000275493.2:c.2369C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024768	COSS1024768	EGFR	COSG35617	ENST00000442591.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	58365907	p.?	c.*28+8450C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+		ENST00000442591.1:c.*28+8450C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024768	COSS1024768	EGFR	COSG35617	ENST00000454757.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	61857897	p.T737M	c.2210C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+	ENSP00000395243.2:p.Thr737Met	ENST00000454757.2:c.2210C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024768	COSS1024768	EGFR	COSG35617	ENST00000455089.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	62640703	p.T745M	c.2234C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+	ENSP00000415559.1:p.Thr745Met	ENST00000455089.1:c.2234C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024775	COSS1024775	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	22472073	p.T790M	c.2369C>T	C	T	COSO29914826	17020982		het	7	55249071	55249071	+	ENSP00000275493.2:p.Thr790Met	ENST00000275493.2:c.2369C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024775	COSS1024775	EGFR	COSG35617	ENST00000442591.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	58365907	p.?	c.*28+8450C>T	C	T	COSO29914826	17020982		het	7	55249071	55249071	+		ENST00000442591.1:c.*28+8450C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024775	COSS1024775	EGFR	COSG35617	ENST00000454757.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	61857897	p.T737M	c.2210C>T	C	T	COSO29914826	17020982		het	7	55249071	55249071	+	ENSP00000395243.2:p.Thr737Met	ENST00000454757.2:c.2210C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024775	COSS1024775	EGFR	COSG35617	ENST00000455089.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	62640703	p.T745M	c.2234C>T	C	T	COSO29914826	17020982		het	7	55249071	55249071	+	ENSP00000415559.1:p.Thr745Met	ENST00000455089.1:c.2234C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024776	COSS1024776	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	22472073	p.T790M	c.2369C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+	ENSP00000275493.2:p.Thr790Met	ENST00000275493.2:c.2369C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024776	COSS1024776	EGFR	COSG35617	ENST00000442591.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	58365907	p.?	c.*28+8450C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+		ENST00000442591.1:c.*28+8450C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024776	COSS1024776	EGFR	COSG35617	ENST00000454757.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	61857897	p.T737M	c.2210C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+	ENSP00000395243.2:p.Thr737Met	ENST00000454757.2:c.2210C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024776	COSS1024776	EGFR	COSG35617	ENST00000455089.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	62640703	p.T745M	c.2234C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+	ENSP00000415559.1:p.Thr745Met	ENST00000455089.1:c.2234C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024780	COSS1024780	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	22472073	p.T790M	c.2369C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+	ENSP00000275493.2:p.Thr790Met	ENST00000275493.2:c.2369C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024780	COSS1024780	EGFR	COSG35617	ENST00000442591.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	58365907	p.?	c.*28+8450C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+		ENST00000442591.1:c.*28+8450C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024780	COSS1024780	EGFR	COSG35617	ENST00000454757.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	61857897	p.T737M	c.2210C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+	ENSP00000395243.2:p.Thr737Met	ENST00000454757.2:c.2210C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1024780	COSS1024780	EGFR	COSG35617	ENST00000455089.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	62640703	p.T745M	c.2234C>T	C	T	COSO29914826	17020982			7	55249071	55249071	+	ENSP00000415559.1:p.Thr745Met	ENST00000455089.1:c.2234C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1031893	COSS1031893	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51772923	COSM21984	22496385	p.D761Y	c.2281G>T	G	T	COSO29914826	17085664		het	7	55242511	55242511	+	ENSP00000275493.2:p.Asp761Tyr	ENST00000275493.2:c.2281G>T	7:g.55242511G>T	Confirmed somatic variant
1031893	COSS1031893	EGFR	COSG35617	ENST00000442591.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51772923	COSM21984	58371789	p.?	c.*28+1890G>T	G	T	COSO29914826	17085664		het	7	55242511	55242511	+		ENST00000442591.1:c.*28+1890G>T	7:g.55242511G>T	Confirmed somatic variant
1031893	COSS1031893	EGFR	COSG35617	ENST00000454757.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51772923	COSM21984	61863234	p.D708Y	c.2122G>T	G	T	COSO29914826	17085664		het	7	55242511	55242511	+	ENSP00000395243.2:p.Asp708Tyr	ENST00000454757.2:c.2122G>T	7:g.55242511G>T	Confirmed somatic variant
1031893	COSS1031893	EGFR	COSG35617	ENST00000455089.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51772923	COSM21984	62645034	p.D716Y	c.2146G>T	G	T	COSO29914826	17085664		het	7	55242511	55242511	+	ENSP00000415559.1:p.Asp716Tyr	ENST00000455089.1:c.2146G>T	7:g.55242511G>T	Confirmed somatic variant
1031894	COSS1031894	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence		COSM21943	189355174	p.T790M	c.?			COSO29914826	17085664						+	ENSP00000275493.2:p.Thr790Met			Reported in another cancer sample as somatic
1031895	COSS1031895	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence		COSM21943	189355174	p.T790M	c.?			COSO29914826	17085664						+	ENSP00000275493.2:p.Thr790Met			Reported in another cancer sample as somatic
1031896	COSS1031896	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence		COSM21943	189355174	p.T790M	c.?			COSO29914826	17085664						+	ENSP00000275493.2:p.Thr790Met			Reported in another cancer sample as somatic
1031897	COSS1031897	EGFR	COSG35617	ENST00000275493.2	Yes	Erlotinib	Erlotinib clinical resistant recurrence		COSM21943	189355174	p.T790M	c.?			COSO29914826	17085664						+	ENSP00000275493.2:p.Thr790Met			Reported in another cancer sample as somatic
1031898	COSS1031898	EGFR	COSG35617	ENST00000275493.2	Yes	Erlotinib	Erlotinib clinical resistant recurrence		COSM21943	189355174	p.T790M	c.?			COSO29914826	17085664						+	ENSP00000275493.2:p.Thr790Met			Reported in another cancer sample as somatic
1031899	COSS1031899	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence		COSM21943	189355174	p.T790M	c.?			COSO29914826	17085664						+	ENSP00000275493.2:p.Thr790Met			Reported in another cancer sample as somatic
1031900	COSS1031900	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence		COSM21943	189355174	p.T790M	c.?			COSO29914826	17085664						+	ENSP00000275493.2:p.Thr790Met			Reported in another cancer sample as somatic
1040049	COSS1040049	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	22472073	p.T790M	c.2369C>T	C	T	COSO29974826	17180521			7	55249071	55249071	+	ENSP00000275493.2:p.Thr790Met	ENST00000275493.2:c.2369C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1040049	COSS1040049	EGFR	COSG35617	ENST00000442591.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	58365907	p.?	c.*28+8450C>T	C	T	COSO29974826	17180521			7	55249071	55249071	+		ENST00000442591.1:c.*28+8450C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1040049	COSS1040049	EGFR	COSG35617	ENST00000454757.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	61857897	p.T737M	c.2210C>T	C	T	COSO29974826	17180521			7	55249071	55249071	+	ENSP00000395243.2:p.Thr737Met	ENST00000454757.2:c.2210C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1040049	COSS1040049	EGFR	COSG35617	ENST00000455089.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	62640703	p.T745M	c.2234C>T	C	T	COSO29974826	17180521			7	55249071	55249071	+	ENSP00000415559.1:p.Thr745Met	ENST00000455089.1:c.2234C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1043871	COSS1043871	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical primary non response 	COSV51765492	COSM6240	22472073	p.T790M	c.2369C>T	C	T	COSO29915473	17192902			7	55249071	55249071	+	ENSP00000275493.2:p.Thr790Met	ENST00000275493.2:c.2369C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1043871	COSS1043871	EGFR	COSG35617	ENST00000442591.1	Yes	Gefitinib	Gefitinib clinical primary non response 	COSV51765492	COSM6240	58365907	p.?	c.*28+8450C>T	C	T	COSO29915473	17192902			7	55249071	55249071	+		ENST00000442591.1:c.*28+8450C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1043871	COSS1043871	EGFR	COSG35617	ENST00000454757.2	Yes	Gefitinib	Gefitinib clinical primary non response 	COSV51765492	COSM6240	61857897	p.T737M	c.2210C>T	C	T	COSO29915473	17192902			7	55249071	55249071	+	ENSP00000395243.2:p.Thr737Met	ENST00000454757.2:c.2210C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1043871	COSS1043871	EGFR	COSG35617	ENST00000455089.1	Yes	Gefitinib	Gefitinib clinical primary non response 	COSV51765492	COSM6240	62640703	p.T745M	c.2234C>T	C	T	COSO29915473	17192902			7	55249071	55249071	+	ENSP00000415559.1:p.Thr745Met	ENST00000455089.1:c.2234C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1047910	COSS1047910	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	22472073	p.T790M	c.2369C>T	C	T	COSO29954826	17335935		het	7	55249071	55249071	+	ENSP00000275493.2:p.Thr790Met	ENST00000275493.2:c.2369C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1047910	COSS1047910	EGFR	COSG35617	ENST00000442591.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	58365907	p.?	c.*28+8450C>T	C	T	COSO29954826	17335935		het	7	55249071	55249071	+		ENST00000442591.1:c.*28+8450C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1047910	COSS1047910	EGFR	COSG35617	ENST00000454757.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	61857897	p.T737M	c.2210C>T	C	T	COSO29954826	17335935		het	7	55249071	55249071	+	ENSP00000395243.2:p.Thr737Met	ENST00000454757.2:c.2210C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1047910	COSS1047910	EGFR	COSG35617	ENST00000455089.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	62640703	p.T745M	c.2234C>T	C	T	COSO29954826	17335935		het	7	55249071	55249071	+	ENSP00000415559.1:p.Thr745Met	ENST00000455089.1:c.2234C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
11	COSS1069271	PDGFRA	COSG38207	ENST00000257290.5	Yes	Imatinib	Imatinib clinical primary non response		COSM12432	189355509	p.D842V	c.?			COSO36075546	15930355						+	ENSP00000257290.5:p.Asp842Val			Reported in another cancer sample as somatic
11	COSS2770742	NT5C2	COSG53846	ENST00000343289.5	Yes	Purine	Purine analogue clinical resistant recurrence	COSV58414509	COSM914303	31970947	p.R367Q	c.1100G>A	C	T	COSO27984908	28157215		het	10	104852955	104852955	-	ENSP00000339479.5:p.Arg367Gln	ENST00000343289.5:c.1100G>A	10:g.104852955C>T	Reported in another cancer sample as somatic
11	COSS2770742	NT5C2	COSG53846	ENST00000343289.5	Yes	Purine	Purine analogue clinical resistant recurrence	COSV99056933	COSM7349744	31973134	p.P414S	c.1240C>T	G	A	COSO27984908	28157215		het	10	104850725	104850725	-	ENSP00000339479.5:p.Pro414Ser	ENST00000343289.5:c.1240C>T	10:g.104850725G>A	Reported in another cancer sample as somatic
11	COSS2770742	NT5C2	COSG53846	ENST00000404739.3	Yes	Purine	Purine analogue clinical resistant recurrence	COSV58414509	COSM914303	47499304	p.R367Q	c.1100G>A	C	T	COSO27984908	28157215		het	10	104852955	104852955	-	ENSP00000383960.3:p.Arg367Gln	ENST00000404739.3:c.1100G>A	10:g.104852955C>T	Reported in another cancer sample as somatic
11	COSS2770742	NT5C2	COSG53846	ENST00000404739.3	Yes	Purine	Purine analogue clinical resistant recurrence	COSV99056933	COSM7349744	47501659	p.P414S	c.1240C>T	G	A	COSO27984908	28157215		het	10	104850725	104850725	-	ENSP00000383960.3:p.Pro414Ser	ENST00000404739.3:c.1240C>T	10:g.104850725G>A	Reported in another cancer sample as somatic
11	COSS2770742	NT5C2	COSG53846	ENST00000423468.2	Yes	Purine	Purine analogue clinical resistant recurrence	COSV58414509	COSM914303	53936229	p.R338Q	c.1013G>A	C	T	COSO27984908	28157215		het	10	104852955	104852955	-	ENSP00000392236.2:p.Arg338Gln	ENST00000423468.2:c.1013G>A	10:g.104852955C>T	Reported in another cancer sample as somatic
11	COSS2770742	NT5C2	COSG53846	ENST00000423468.2	Yes	Purine	Purine analogue clinical resistant recurrence	COSV99056933	COSM7349744	53936438	p.P385S	c.1153C>T	G	A	COSO27984908	28157215		het	10	104850725	104850725	-	ENSP00000392236.2:p.Pro385Ser	ENST00000423468.2:c.1153C>T	10:g.104850725G>A	Reported in another cancer sample as somatic
1103803	COSS1103803	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	22472073	p.T790M	c.2369C>T	C	T	COSO29914826	18271876			7	55249071	55249071	+	ENSP00000275493.2:p.Thr790Met	ENST00000275493.2:c.2369C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1103803	COSS1103803	EGFR	COSG35617	ENST00000442591.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	58365907	p.?	c.*28+8450C>T	C	T	COSO29914826	18271876			7	55249071	55249071	+		ENST00000442591.1:c.*28+8450C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1103803	COSS1103803	EGFR	COSG35617	ENST00000454757.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	61857897	p.T737M	c.2210C>T	C	T	COSO29914826	18271876			7	55249071	55249071	+	ENSP00000395243.2:p.Thr737Met	ENST00000454757.2:c.2210C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1103803	COSS1103803	EGFR	COSG35617	ENST00000455089.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	62640703	p.T745M	c.2234C>T	C	T	COSO29914826	18271876			7	55249071	55249071	+	ENSP00000415559.1:p.Thr745Met	ENST00000455089.1:c.2234C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1103805	COSS1103805	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	22472073	p.T790M	c.2369C>T	C	T	COSO29914826	18271876			7	55249071	55249071	+	ENSP00000275493.2:p.Thr790Met	ENST00000275493.2:c.2369C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1103805	COSS1103805	EGFR	COSG35617	ENST00000442591.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	58365907	p.?	c.*28+8450C>T	C	T	COSO29914826	18271876			7	55249071	55249071	+		ENST00000442591.1:c.*28+8450C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1103805	COSS1103805	EGFR	COSG35617	ENST00000454757.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	61857897	p.T737M	c.2210C>T	C	T	COSO29914826	18271876			7	55249071	55249071	+	ENSP00000395243.2:p.Thr737Met	ENST00000454757.2:c.2210C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1103805	COSS1103805	EGFR	COSG35617	ENST00000455089.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	62640703	p.T745M	c.2234C>T	C	T	COSO29914826	18271876			7	55249071	55249071	+	ENSP00000415559.1:p.Thr745Met	ENST00000455089.1:c.2234C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1103807	COSS1103807	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	22472073	p.T790M	c.2369C>T	C	T	COSO29914826	18271876			7	55249071	55249071	+	ENSP00000275493.2:p.Thr790Met	ENST00000275493.2:c.2369C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1103807	COSS1103807	EGFR	COSG35617	ENST00000442591.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	58365907	p.?	c.*28+8450C>T	C	T	COSO29914826	18271876			7	55249071	55249071	+		ENST00000442591.1:c.*28+8450C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1103807	COSS1103807	EGFR	COSG35617	ENST00000454757.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	61857897	p.T737M	c.2210C>T	C	T	COSO29914826	18271876			7	55249071	55249071	+	ENSP00000395243.2:p.Thr737Met	ENST00000454757.2:c.2210C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1103807	COSS1103807	EGFR	COSG35617	ENST00000455089.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	62640703	p.T745M	c.2234C>T	C	T	COSO29914826	18271876			7	55249071	55249071	+	ENSP00000415559.1:p.Thr745Met	ENST00000455089.1:c.2234C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1103809	COSS1103809	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	22472073	p.T790M	c.2369C>T	C	T	COSO29914826	18271876			7	55249071	55249071	+	ENSP00000275493.2:p.Thr790Met	ENST00000275493.2:c.2369C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1103809	COSS1103809	EGFR	COSG35617	ENST00000442591.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	58365907	p.?	c.*28+8450C>T	C	T	COSO29914826	18271876			7	55249071	55249071	+		ENST00000442591.1:c.*28+8450C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1103809	COSS1103809	EGFR	COSG35617	ENST00000454757.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	61857897	p.T737M	c.2210C>T	C	T	COSO29914826	18271876			7	55249071	55249071	+	ENSP00000395243.2:p.Thr737Met	ENST00000454757.2:c.2210C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1103809	COSS1103809	EGFR	COSG35617	ENST00000455089.1	Yes	Gefitinib	Gefitinib clinical resistant recurrence	COSV51765492	COSM6240	62640703	p.T745M	c.2234C>T	C	T	COSO29914826	18271876			7	55249071	55249071	+	ENSP00000415559.1:p.Thr745Met	ENST00000455089.1:c.2234C>T	7:g.55249071C>T	Reported in another cancer sample as somatic
1108052	COSS1108052	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence		COSM21943	189355174	p.T790M	c.?			COSO29915645	17973572						+	ENSP00000275493.2:p.Thr790Met			Reported in another cancer sample as somatic
1120916	COSS1120916	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical primary non response 		COSM21943	189355174	p.T790M	c.?			COSO29915674	18509184						+	ENSP00000275493.2:p.Thr790Met			Reported in another cancer sample as somatic
1122168	COSS1122168	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical resistant recurrence		COSM21943	189355174	p.T790M	c.?			COSO29914826	18379370						+	ENSP00000275493.2:p.Thr790Met			Reported in another cancer sample as somatic
1122357	COSS1122357	KIT	COSG30790	ENST00000288135.5	Yes	Imatinib	Imatinib clinical resistant recurrence		COSM27127	189355582	p.D816H	c.?			COSO31355381	17875769						+	ENSP00000288135.5:p.Asp816His			Reported in another cancer sample as somatic
1122359	COSS1122359	KIT	COSG30790	ENST00000288135.5	Yes	Imatinib	Imatinib clinical resistant recurrence		COSM24707	189355499	p.Y823D	c.?			COSO31355381	17875769						+	ENSP00000288135.5:p.Tyr823Asp			Reported in another cancer sample as somatic
1122361	COSS1122361	KIT	COSG30790	ENST00000288135.5	Yes	Imatinib	Imatinib clinical resistant recurrence		COSM24707	189355499	p.Y823D	c.?			COSO31355381	17875769						+	ENSP00000288135.5:p.Tyr823Asp			Reported in another cancer sample as somatic
1122363	COSS1122363	KIT	COSG30790	ENST00000288135.5	Yes	Imatinib	Imatinib clinical resistant recurrence		COSM19023	189355503	p.N822K	c.?			COSO31355381	17875769						+	ENSP00000288135.5:p.Asn822Lys			Reported in another cancer sample as somatic
1122365	COSS1122365	KIT	COSG30790	ENST00000288135.5	Yes	Imatinib	Imatinib clinical resistant recurrence		COSM24709	189355733	p.V654A	c.?			COSO31355381	17875769						+	ENSP00000288135.5:p.Val654Ala			Reported in another cancer sample as somatic
1122367	COSS1122367	KIT	COSG30790	ENST00000288135.5	Yes	Imatinib	Imatinib clinical resistant recurrence		COSM24709	189355733	p.V654A	c.?			COSO31355381	17875769						+	ENSP00000288135.5:p.Val654Ala			Reported in another cancer sample as somatic
1122369	COSS1122369	KIT	COSG30790	ENST00000288135.5	Yes	Imatinib	Imatinib clinical resistant recurrence		COSM27127	189355582	p.D816H	c.?			COSO31355381	17875769						+	ENSP00000288135.5:p.Asp816His			Reported in another cancer sample as somatic
1122371	COSS1122371	KIT	COSG30790	ENST00000288135.5	Yes	Imatinib	Imatinib clinical resistant recurrence		COSM24641	189360081	p.C809G	c.?			COSO31355381	17875769						+				Reported in another cancer sample as somatic
1135554	COSS1135554	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical primary non response 		COSM21943	189355174	p.T790M	c.?			COSO29914826	18676761						+	ENSP00000275493.2:p.Thr790Met			Reported in another cancer sample as somatic
1135555	COSS1135555	EGFR	COSG35617	ENST00000275493.2	Yes	Gefitinib	Gefitinib clinical primary non response 		COSM21943	189355174	p.T790M	c.?			COSO29914826	18676761						+	ENSP00000275493.2:p.Thr790Met			Reported in another cancer sample as somatic
